Exploration of therapeutic targets for sexual dysfunctions: Lessons learned from the failed stories

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 3, 2011, Pages 325-340

  Abdel Hamid, Ibrahim A ^a   Andersson, Karl Erik ^b   Salonia, Andrea ^c  

^a MANSOURA UNIVERSITY   (Egypt)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Adrenergic receptors; Dopamine receptors; Erectile dysfunction; Female sexual dysfunctions; Lessons learned; PDE5 enzymes; Premature ejaculation; Serotonergic transporters; Sexual dysfunctions; Therapeutic targets

Indexed keywords

3 [3 [4 [4 FLUORO 2 (2,2,2 TRIFLUOROETHOXY)PHENYL] 1 PIPERAZINYL]PROPYL] 5 METHYL 1H PYRIMIDINE 2,4 DIONE; 5 CYANO 3 [2 (DIMETHYLAMINOMETHYL)CYCLOPROPYL]INDOLE; ABT 724; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; BMS 505; BREMELANOTIDE; CLOMIPRAMINE; DAPOXETINE; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LI 301; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 (2 CYANOPHENYL) 1 PIPERAZINYLMETHYL] 3 METHYLBENZAMIDE; PAPAVERINE; PAROXETINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PIP 3EA; PROPRANOLOL; RO 700003; RX 10100; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; TADALAFIL; TRAMADOL; TRAZODONE; UK 390957; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VI 0162; YOHIMBINE;

DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; IMPOTENCE; LACRIMATION; NAUSEA; NONHUMAN; NOSE CONGESTION; PAIN; PENILE PAIN; PREMATURE EJACULATION; REVIEW; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VOMITING; YAWNING;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; EJACULATION; ERECTILE DYSFUNCTION; FEMALE; HUMANS; MALE; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL;

EID: 79951651211     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.551008     Document Type: Review

References (155)

1. Zheng CJ, Han LY, Yap CW, et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006;58:259-79
2. Zheng C, Han L, Yap CW, et al. Progress and problems in the exploration of therapeutic targets. Drug Discov Today 2006;11:412-20
3. Rajfer J. Discovery of NO in the penis. Int J Impot Res 2008;20:431-6.
4. Schmid EF, Smith DA. Keynote review: is declining innovation in the pharmaceutical industry a myth? Drug Discov Today 2005;10:1031-9 (Pubitemid 41074141)
5. Verkman AS. Drug discovery in academia. Am J Physiol Cell Physiol 2004;286:C465-74 (Pubitemid 38292650)
6. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5:821-34. (Pubitemid 44480536)
7. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30 (Pubitemid 37361545)
8. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv Drug Deliv Rev 2001;46:3-26 (Pubitemid 33653411)
9. Hardy LW, Peet NP. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Drug Discov Today 2004;9:117-16
10. Walke DW, Han C, Shaw J, et al. In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol 2001;12:626-31 (Pubitemid 34146513)
11. Shaikh SA, Jain T, Sandhu G, et al. From drug target to leads-sketching a physicochemical pathway for lead molecule design in silico. Curr Pharm Des 2007;13:3454-70 (Pubitemid 350238936)
12. Smith C. Drug target validation: hitting the target. Nature 2003;422(6929):341, 343, 345
13. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236
14. Traish AM, Netsuwan N, Daley J, et al. A heterogeneous population of alpha 1 adrenergic receptors mediates contraction of human corpus cavernosum smooth muscle to norepinephrine. J Urol 1995;153:222-7 (Pubitemid 24379846)
15. Traish AM, Gupta S, Toselli P, et al. Identification of alpha 1-adrenergic receptor subtypes in human corpus cavernosum tissue and in cultured trabecular smooth muscle cells. Receptor 1995;5:145-57
16. Traish AM, Moreland RB, Huang YH, Goldstein I. Expression of functional alpha2-adrenergic receptor subtypes in human corpus cavernosum and in cultured trabecular smooth muscle cells. Recept Signal Transduct 1997;7:55-67
17. Goepel M, Krege S, Price DT, et al. Characterization of alpha-adrenoceptor subtypes in the corpus cavernosum of patients undergoing sex change surgery. J Urol 1999;162:1793-9 (Pubitemid 29474731)
18. Krege S, Goepel M, Sperling H, Michel MC. Affinity of trazodone for human penile a1- and a2-adrenoceptors. BJU Int 2000; 85:959-61
19. Sperling H, Lorenz A, Krege S, et al. An extract from the bark of Aspidosperma quebracho blanco binds to human penile alpha-adrenoceptors. J Urol 2002;168:160-3 (Pubitemid 34640806)
20. Davis B, Chapple C, Chess-Williams R. The alpha1L-adrenoceptor mediates contraction in human erectile tissue (Abstract 406). Eur Urol 1999;35(Suppl 2):102
21. Rees RW, Ralph DJ, Royle M, et al. Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum. Br J Pharmacol 2001;133:455-8 (Pubitemid 32591910)
22. Morton JS, Daly CJ, Jackson VM, McGrath GC. alpha1A-Adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries. Br J Pharmacol 2007;150:112-20 (Pubitemid 46094676)
23. Traish AM, Kim NN, Goldstein I, Moreland RB. Alpha-adrenergic receptors in the penis: identification, characterization, and physiological function. J Androl 1999;20:671-82
24. Gupta S, Moreland RB, Daley JT, et al. Corpus cavernosum smooth muscle expresses functional postsynaptic alpha-2-adrenergic receptors. Br J Phannacol 1998:123:1237-45 (Pubitemid 28120524)
25. Molderings GJ, G€othert M,van Ahlen H, Porst H. Noradrenaline release in human corpus cavernosum and its modulation via presynaptic alpha 2-adrenoceptors. Fundam Clin Pharmacol 1989;3:497-504 (Pubitemid 20017213)
26. de Tejada IS, Kim NN, Goldstein I, Traish AM. (2000) Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum. Int J Impot Res 2000;12(Suppl 1):S20-5 (Pubitemid 30255743)
27. Morton JS, Daly CJ, Jackson VM, McGrath JC. Alpha(1A)-adrenoceptors mediate contractions to phenylephrine in rabbit penile arteries. Br J Pharmacol 2007;150:112-20 (Pubitemid 46094676)
28. Cirino G, Sorrentino R, di Villa Bianca, et al. Involvement of beta3-adrenergic receptor activation via cyclic GMP-but not NO-dependent mechanisms in humancorpus cavernosum function. Proc Natl Acad Sci USA 2003;100:5531-6 (Pubitemid 36542739)
29. Levin RM, Wein AJ. Adrenergic alpha-receptors outnumber beta-receptors in human penile corpus cavernosum. Invest Urol 1980;18:225-6 (Pubitemid 11226248)
30. Adaikan PG, Karim SMM. Adrenoreceptors in the human penis. J Auton Pharmacol 1981;1:199-203 (Pubitemid 11025242)
31. Teixeira CE, Baracat JS, Zanesco A, et al. Atypical beta-adrenoceptor subtypes mediate relaxations of Rabbit Corpus Cavernosum. J Pharmacol Exp Ther 2004;309:587-93 (Pubitemid 38542611)
32. Recio P, López PG, Fernández JL, Garcia-Sacristán A. Pharmacological characterization of adrenoceptors in horse corpus cavernosum penis. J Auton Pharmacol 1997;17:191-8 (Pubitemid 27331475)
33. Brock G. Oral phentolamine (Vasomax). Drugs Today (Barc) 2000;36:121-4
34. Goldstein I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. Int J Impot Res 2000;12(Suppl 1):S75-80 (Pubitemid 30255750)
35. Goldstein I, Carson C, Rosen R, Islam A. Vasomax for the treatment of male erectile dysfunction. World J Urol 2001;19:51-6 (Pubitemid 33777033)
36. Padma-Nathan H, Goldstein I, Klimberg I, et al. Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction. Int J Impot Res 2002;14:266-70 (Pubitemid 34947731)
37. Poulet FM, Berardi MR, Halliwell W, et al. Development of hibernomas in rats dosed with phentolamine mesylate during the 24-month carcinogenicity study. Toxicol Pathol 2004;32:558-66. (Pubitemid 39258461)
38. Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination forvasculogenic impotence. J Urol 1985;133:39-41 (Pubitemid 15195738)
39. Robinette M, Moffat MJ. Intracorporeal injection of papaverine and phentolamine in the management of impotence. Br J Urol 1986;58:692-5 (Pubitemid 17215764)
40. Keogh EJ, Watters GR, Earle CM, et al. Treatment of impotence by intracavernosal injections. A comparison of papaverine and papaverine and phentolamine: a double-blind crossover trial. J Urol 1989;142:726-8
41. Bechara A, Casabe A, Cheliz G, et al. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction. J Urol 1997:157:2132-34 (Pubitemid 27208658)
42. Keijzers GB. Aviptadil (Senatek). Curr Opin Investig Drugs 2001;2(4):545-9
43. Shah PJ, Dinsmore W, Oakes RA, Hackett G. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesilate. Curr Med Res Opin 2007;23:2577-83 (Pubitemid 350033460)
44. Choppin A, Blue DR, Hegde SS, et al. Evaluation of oral RO70-0004/003, an alpha 1 Aadrenoceptor antagonist, in the treatment of male erectile dysfunction. Int J Impot Res 2001;13:157-61 (Pubitemid 32587262)
45. Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res 2000;12(Suppl 1):S70-4 (Pubitemid 30255749)
46. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50
47. Krege S, Goepel M, Sperling H, 0Michel MC. Affinity of trazodone for human penile alpha1- and alpha2-adrenoceptors. BJU Int 2000;85:959-61 (Pubitemid 30242807)
48. Fink HA, MacDonald R, Rutks IR, Wilt TJ. Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int 2003;92:441-6 (Pubitemid 37100526)
49. van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)- adrenoceptor antagonists on male sexual function. Drugs 2006;66:287-301 (Pubitemid 46291765)
50. Hosoda C, Tanoue A, Shibano M, et al. Correlation between vasoconstrictor roles and mRNA expression of alpha1-adrenoceptor subtypes in blood vessels of genetically engineered mice. Br J Pharmacol 2005;146:456-66 (Pubitemid 41486688)
51. Sanbe A, Tanaka Y, Fujiwara Y, et al. Alpha1-adrenoceptors are required for normal male sexual function. Br J Pharmacol 2007;152:332-40 (Pubitemid 47511249)
52. Methven L, Simpson PC, McGrath JC. Alpha1A/B-knockout mice explain the native alpha1D-adrenoceptor's role in vasoconstriction and show that its location is independent of the other alpha1-subtypes. Br J Pharmacol 2009;158:1663-75
53. Chaudhry A, Granneman JG. Differential regulation of functional responses by beta-adrenergic receptor subtypes in brown adipocytes. Am J Physiol 1999;277:R147-53 (Pubitemid 29356788)
54. Lindquist JM, Fredriksson JM, Rehnmark S, et al. Beta 3- and alpha1-adrenergic Erk1/2 activation is Src- but not Gi-mediated in Brown adipocytes. J Biol Chem 2000;275:22670-7 (Pubitemid 30646148)
55. Zahir M, Gould L. Phentolamine and beta-adrenergic receptors. J Clin Pharmacol New Drugs 1971;11:197-203
56. Hong SS, Bavadekar SA, Lee SI, et al. Bioisosteric phentolamine analogs as potent alpha-adrenergic antagonists. Bioorg Med Chem Lett 2005;15:4691-5 (Pubitemid 41356663)
57. Bavadekar SA, Hong SS, Lee SI, et al. Bioisosteric phentolamine analogs as selective human alpha(2)- versus alpha(1)-adrenoceptor ligands. Eur J Pharmacol 2008;590:53-60
58. Meador-Woodruff JH. Update on dopamine receptors. Ann Clin Psychiatry 1994;6:79-90 (Pubitemid 24312171)
59. Bj€orklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30:194-202 (Pubitemid 46654237)
60. Hull EM, Du J, Lorrain DS, Matuszewich L. Extracellular dopamine in the medial preoptic area: implications for sexual motivation and hormonal control of copulation. J Neurosci 1995;15:7465-71
61. Melis MR, Succu S, Mascia MS, et al. Extra-cellular dopamine increases in the paraventricular nucleus of male rats during sexual activity. Eur J Neurosci 2003;17:1266-72 (Pubitemid 36459780)
62. Melis MR, Argiolas A. Dopamine and sexual behaviour. Neurosci Biobehav Rev 1995;19:19-38
63. Lal S, Tesfaye Y, Thavundayil JX, et al. Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:329-39 (Pubitemid 19163785)
64. Andersson KE, Argiolas A, Burnett A, et al. Future treatment targets. Sexual medicine: sexual dysfunction in men and women. In: Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi , editors, Distributor editions 21. Health Publications Ltd., Paris; 2004. p. 567-603
65. Argiolas A, Melis MR. Central control of penile erection: role of the paraventricular nucleus of the hypothalamus. Prog Neurobiol 2005;76:1-21 (Pubitemid 41033401)
66. Melis MR, Succu S, Sanna F, et al.PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain. Eur J Neurosci 2006;24:2021-30 (Pubitemid 44583486)
67. Succu S, Sanna F, Melis T, et al. Stimulation of dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces penile erection and increases extra-cellular dopamine in the nucleus accumbens: involvement of central oxytocin. Neuropharmacology 2007;52:1034-43 (Pubitemid 46227490)
68. Melis MR, Succu S, Argiolas A. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur J Neurosci 1996;8:2056-63 (Pubitemid 26345777)
69. Matsumoto K, Yoshida M, Andersson KE, Hedlund P. Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum. Br J Pharmacol 2005;146:259-67 (Pubitemid 43079966)
70. d'Emmanuele di Villa Bianca R, Sorrentino R, et al. Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips. Int J Impot Res 2005;17:127-33 (Pubitemid 40434585)
71. Stief C, Padley RJ, Perdok RJ, Sleep DJ. Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: pooled data from three placebo-controlled, fixed-dose cross-over studies. Eur Urol 2002;(Suppl 1):12-36.
72. Heaton J, Sleep D, Perdok R, et al. Efficacy and safety of Uprima (apomorphine SL) in patients with documented comorbidities of hypertension, coronary artery disease (CAD) or diabetes. Int J Impotence Res 2001;13(Suppl 4):S32, Abstr.87
73. Gontero P, D'Antonio R, Pretti G, et al. Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res 2005;17:80-5 (Pubitemid 40299998)
74. Perimenis P, Gyftopoulos K, Giannitsas K, et al. A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. Int J Impot Res 2004;16:2-7 (Pubitemid 38401552)
75. Strebel RT, Reitz A, Tenti G, et al. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. BJU Int 2004;93:100-4 (Pubitemid 38112976)
76. Giammusso B, Colpi GM, Cormio L, et al. An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008;81:409-15
77. Afif-Abdo J, Teloken C, Damiaõ R, et al. Comparative cross-over study of sildenafil and apomorphine for treatingerectile dysfunction. BJU Int 2008;102:829-34
78. Strebel RT, Reitz A, Tenti G, et al. Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. BJU Int 2004;93:100-4 (Pubitemid 38112976)
79. Pavone C, Curto F, Anello G, et al. Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2008;179(5 Suppl):S92-4 (Pubitemid 351483919)
80. Porst H, Behre HM, Jungwirth A, Burkart M. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction-an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007;12:61-7 (Pubitemid 46394640)
81. Perimenis P, Markou S, Gyftopoulos K, et al. Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia 2004;36:106-10 (Pubitemid 38901426)
82. Maclennan KM, Boshier A, Wilton LV, Shakir SA. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 2006;98:125-31 (Pubitemid 43885519)
83. Porst H. Oral Pharmacotherapy of Erectile Dysfunction in 'Standard Practice in Sexual Medicine', Porst H, Buvat J, editors, 1st edition, 2006 International Society for Sexual Medicine Blackwell Publishing, Oxoford, 2006;p. 75-93
84. Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticleswith different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci 2010;100:547-57
85. Andersson KE. Pharmacology of penile erection. Pharmacol Rev 2001;53:417-50
86. Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med 2010;7:1508-17
87. Carson CC, Dean JD. Management of erectile dysfunction in clinical practice. 1st edition. Springer-Verlag Limited,London; 2007. p. 66-70
88. Patel MV, Kolasa T, Mortell K, et al. Discovery of 3-methyl-N-(1-oxy- 3',4',5',6'-tetrahydro-2'H-[2,4'- bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem 2006;49:7450-65 (Pubitemid 44913404)
89. Melis MR, Succu S, Sanna F, et al. PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain. Eur J Neurosci 2006;24:2021-30 (Pubitemid 44583486)
90. Brioni JD, Moreland RB, Cowart M, et al. 'Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats'. Proc Natl Acad Sci USA 2004;101:6758-63 (Pubitemid 38586047)
91. Bitner RS, Nikkel AL, Otte S, et al. Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: evidence of natural coupling involvingimmediate early gene induction and mitogen activated protein kinase phosphorylation. Neuropharmacology 2006;50:521-31
92. Giuliano F, Clement P. Neuroanatomy and physiology of ejaculation. Annu Rev Sex Res 2005;16:190-216 (Pubitemid 43836779)
93. Coolen LM, Allard J, Truitt WA, McKenna KE. Central regulation of ejaculation. Physiol Behav 2004;83:203-15 (Pubitemid 39361566)
94. Krüger TH, Hartmann U, Schedlowski M. Prolactinergic and dopaminergic mechanisms underlying sexual arousal and orgasm in humans. World J Urol 2005;23:130-8 (Pubitemid 41051504)
95. Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 2004;83:291-307 (Pubitemid 39361571)
96. de Jong TR, Veening JG, Waldinger MD, et al. Serotonin and the neurobiology of the ejaculatory threshold. Neurosci Biobehav Rev 2006;30:893-907 (Pubitemid 44292850)
97. Gravitt K, Marson L. Effect of the destruction of cells containing the serotonin reuptake transporter on urethrogenital Reflexes. J Sex Med 2007;4:322-31 (Pubitemid 46394706)
98. Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-94 (Pubitemid 27514710)
99. Waldinger MD. Premature ejaculation: state of the art. Urol Clin N Am 2007;34:591-9 (Pubitemid 350029951)
100. Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004;16:369-81 (Pubitemid 39273766)
101. Ahlenius S Larsson K. Synergistic actions of the 5-HT1A antagonist WAY-100635 and citalopram on male rat ejaculatory behavior. Eur J Pharmacol 1999;379:1-6 (Pubitemid 29492941)
102. Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets 2009;13:175-93
103. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000;25:255-61 (Pubitemid 30641002)
104. Waldinger MD. Emerging drugs for premature ejaculation. Expert Opin Emerg Drugs 2006;11:99-109
105. Waldinger MD, Schweitzer DH. Premature ejaculation and pharmaceutical company-based medicine: the dapoxetine case. J Sex Med 2008;5(4):966-97
106. McMahon CG, Althof SE, Kaufman JM, et al. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: Integrated analysis of results from five phase 3 trials. J Sex Med 2010; doi: 10.1111/j.1743-6109.2010. 02097.x
107. Waldinger MD, Zwinderman AH, Olivier B, Schweitzer DH. The majority of men with lifelong premature ejaculation prefer daily drug treatment: an observation study in a consecutive group of Dutch men. J Sex Med 2007;4(1):1028-37 (Pubitemid 47079636)
108. Salonia A, Rocchini L, Sacca A, et al. Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. J Sex Med 2009;6:2868-77.
109. McMahon CG. Long term results of treatment of premature ejaculation with selective serotonin re-uptake inhibitors. Int J Impot Res 2002;14(3 Suppl):S19
110. Waldinger MD. Premature ejaculation: definition and drug treatment. Drugs 2007;67:547-68 (Pubitemid 46440312)
111. Bradley D. Why big pharma needs to learn the three 'R's. Nat Rev Drug Discov 2005;4:446 (Pubitemid 40861965)
112. Taber MT, Wright RN, Molski TF, et al. Neurochemical, pharmacokinetic, and behavioral effects of the novel selective serotonin reuptake inhibitor BMS-505130. Pharmacol Biochem Behav 2005;80:521-8 (Pubitemid 40299354)
113. Giuliano F. 5-HT in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 2007;30:79-84. (Pubitemid 46164860)
114. Azam U. Late-stage clinical development in lower urogenital targets: sexual dysfunction. Br J Pharmacol 2006;147(S2):S153-9 (Pubitemid 43237581)
115. Hoyle CH, Stones RW, Robson T, et al. Innervation of vasculature and microvasculature of the human vagina by NOS and neuropeptide-containing nerves. J Anat 1996;188:633-44 (Pubitemid 26232205)
116. Martin-Alguacil N, Pfaff DW, Shelley DN, Schober JM. Clitoral sexual arousal: an immunocytochemical and innervations study of the clitoris. BJU Int 2008;101:1407-13 (Pubitemid 351623992)
117. Burnett AL, Calvin DC, Silver RI, et al. Immunohistochemical description of nitric oxide synthase isoforms in human clitoris. J Urol 1997;158:75-8. (Pubitemid 27251597)
118. Cellek S, Moncada S. Nitrergic neurotransmission mediates the non-adrenergic non-cholinergic responses in the clitoral corpus cavernosum of the rabbit. Br J Pharmacol 1998;125:1627-9 (Pubitemid 29000807)
119. Park JK, Kim JU, Lee SO, et al. Nitric oxide-cyclic GMP signaling pathway in the regulation of rabbit clitoral cavernosum tone. Exp Biol Med 2002;227:1022-30 (Pubitemid 36008311)
120. Creighton SM, Crouch NS, Foxwell NA, Cellek S. Functional evidence for nitrergic neurotransmission in a human clitoral corpus cavernosum: a case study. Int J Impot Res 2004;16:319-24 (Pubitemid 39273757)
121. Kim SW, Jeong SJ, Munarriz R, et al. Role of the nitric oxide-cyclic GMP pathway in regulation of vaginal blood flow. Int J Impot Res 2003;15:355-61 (Pubitemid 37376941)
122. Traish AM, Botchevar E, Kim NN. Biochemical factors modulating female genital sexual arousal physiology. J Sex Med 2010;7:2925-46
123. D'Amati G, di Gioia CR, Bologna M, et al. Type 5 phosphodiesterase expression in the human vagina. Urology 2002;60:191-5 (Pubitemid 34722984)
124. Uckert S, Oelke M, Waldkirch E, et al. Cyclic adenosine monophosphate and cyclic guanosine monophosphate-phosphodiesterase isoenzymes in human vagina: relation to nitric oxide synthase isoforms and vasoactive intestinal polypeptide-containing nerves. Urology 2005;65:604-10 (Pubitemid 40386034)
125. Oelke M, Hedlund P, Albrecht K, et al. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology 2006;67:1111-16 (Pubitemid 43956445)
126. Uckert S, Oelke M, Albrecht K, et al. Immunohistochemical description of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human labia inora. J Sex Med 2007;4:602-8 (Pubitemid 46779296)
127. Traish A, Moreland RB, Huang YH, et al. Development of human and rabbit vaginal smooth muscle cell cultures: Effects of vasoactive agents on intracellular levels of cyclic nucleotides. Mol Cell Biol Res Commun 1999;2:131-7 (Pubitemid 129532318)
128. Park K, Moreland RB, Goldstein I, et al. Sildenafil inhibits hosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998;249:612-17 (Pubitemid 28441886)
129. Vemulapalli S, Kurowski S. Sildenafil relaxes rabbit clitoral corpus cavernosum. Life Sci 2000;67:23-9 (Pubitemid 30368618)
130. Park K, Moreland RB, Goldstein I, et al. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1998;249:612-17 (Pubitemid 28441886)
131. Angulo J, Cuevas P, Cuevas B, et al. Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs. Int J Impot Res 2003;15:137-41 (Pubitemid 36605003)
132. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. BJOG 2001;108:623-8 (Pubitemid 33646504)
133. Berman JR, Berman LA, Lin H, et al. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J Sex Marital Ther 2001;27:411-20 (Pubitemid 32802775)
134. Berman JR, Berman LA, Toler SM, et al. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333-8 (Pubitemid 37413990)
135. Caruso S, Intelisano G, Farina M, et al. Thefunction of sildenafil on female sexual pathways: a doubleblind, cross-over, placebo-controlled study. Eur J ObstetGynecol Reprod Biol 2003;110:201-6 (Pubitemid 37101319)
136. Basson R, Brotto LA. Sexual psychophysiology and effects of sildenafil citrate in oestrogenised women with acquired genital arousal disorder and impaired orgasm: a randomized controlled trial. BJOG 2003;110:1014-24 (Pubitemid 37338491)
137. Basson R, McInnes R, Smith MD, et al. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med 2002;11:367-77
138. Kaplan SA, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-6 (Pubitemid 29136188)
139. Dasgupta R, Wiseman OJ, Kanabar G, et al. Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004;171:1189-93 (Pubitemid 38327555)
140. Shields KM, Hrometz SL. Use of sildenafil for female sexual dysfunction. Ann Pharmacother 2006;40:931-4 (Pubitemid 43765011)
141. Mayor S. Pfizer will not apply for a licence for sildenafil for women. BMJ 2004;328(7439):542
142. Leiblum SR, Chivers ML. Normal and persistent genital arousal in women: new perspectives. J Sex Marital Ther 2007;33:357-73 (Pubitemid 46868489)
143. Brotto LA, Gehring D, Klein C, et al. Psychophysiological and subjective sexual arousal to visual sexual stimuli in new women. J Psychosom Obstet Gynaecol 2005;26:237-44 (Pubitemid 43879482)
144. Suschinsky KD, Lalumiere ML, Chivers ML. Sex differences in patterns of genital sexual arousal: measurement artifacts or true phenomena? Arch Sex Behav 2009;38:559-73
145. Laan E, Everaerd W. Determinants of female sexual arousal: Psychophysiological theory and data. Annu Rev Sex Res 1995;6:32-76
146. Brown AD, Blagg J, Reynolds DS. Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007;12(17-18):757-66 (Pubitemid 47362785)
147. Chivers M, Rosen RC. PDE5 inhibitors and female sexual response: faulty protocols or paradigms? J Sex Med 2010;7:858-72
148. Wagner G, Ottesen B. Vaginal blood flow during sexual stimulation. Obstetrics & Gynecology 1980;56:621-4 (Pubitemid 11238216)
149. Ottesen B, Pedersen B, Nielsen J, et al. Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women. Peptides 1987;8:797-800
150. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001;4:28-41 (Pubitemid 32448485)
151. Levin RJ. Sex and the human female reproductive tract-what really happens during and after coitus. Int J Impot Res 1998;10(Suppl 1):S14-21
152. Min K, Munarriz R, Yerxa BR, et al. Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits. Fertil Steril 2003;79:393-8 (Pubitemid 36149748)
153. Park K, Han HJ, Kim SW, et al. Expression of aquaporin water channels in rat vagina: potential role in vaginal lubrication. J Sex Med 2008;5:77-82
154. Salonia A, Giraldi A, Chivers ML, et al. Physiology of women's sexual function: basic knowledge and new findings. J Sex Med 2010;7:2637-60
155. Giuliano F, Pfaus J, Balasubramanian S, et al. Experimental models for the study of female and male sexual function. J Sex Med 2010;7:2970-95